Clinical Trial Update: A Feasibility Study Of NAB-Paclitaxel In Combination With Carboplatin As First Line Treatment Of Gastrointestinal Neuroendocrine Carcinomas [Phase 2]

View source ↗

Summary

An update on a Phase 2 feasibility trial evaluating nab-paclitaxel plus carboplatin as first-line therapy for gastrointestinal neuroendocrine carcinomas, with t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Neuroendocrine Carcinomas

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: Barwon Health | Conditions: Gastrointestinal Neuroendocrine Carcinomas | Phase 2 | Status: UNKNOWN